These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 6438041)

  • 1. beta-Lactamase induction by N-formimidoylthienamycin.
    Grappel SF; Giovenella AJ; Newman DJ; Nisbet LJ
    J Antibiot (Tokyo); 1984 Sep; 37(9):1101-2. PubMed ID: 6438041
    [No Abstract]   [Full Text] [Related]  

  • 2. Beta-lactamase induction and aminoglycoside susceptibility in Pseudomonas aeruginosa.
    Stratton CW; Weeks LS; Tausk F
    J Antimicrob Chemother; 1987 Jan; 19(1):21-5. PubMed ID: 3104276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenem-induced resistance to beta-lactams in Pseudomonas aeruginosa.
    Giacometti A; Del Prete MS; Cirioni O; Izat MK; Balducci M; Cesarini AM; Scalise G
    J Chemother; 1995 Nov; 7 Suppl 4():76-7. PubMed ID: 8904115
    [No Abstract]   [Full Text] [Related]  

  • 4. The effects on beta-lactam susceptibility of phenotypic induction and genotypic derepression of beta-lactamase synthesis.
    Shannon K; Phillips I
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():15-22. PubMed ID: 3102451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein.
    Büscher KH; Cullmann W; Dick W; Opferkuch W
    Antimicrob Agents Chemother; 1987 May; 31(5):703-8. PubMed ID: 3111361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imipenem-induced resistance to antipseudomonal beta-lactams in Pseudomonas aeruginosa.
    Tausk F; Evans ME; Patterson LS; Federspiel CF; Stratton CW
    Antimicrob Agents Chemother; 1985 Jul; 28(1):41-5. PubMed ID: 3929679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imipenem resistance in Pseudomonas aeruginosa is due to diminished expression of outer membrane proteins.
    Büscher KH; Cullmann W; Dick W; Wendt S; Opferkuch W
    J Infect Dis; 1987 Oct; 156(4):681-4. PubMed ID: 3114392
    [No Abstract]   [Full Text] [Related]  

  • 8. Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against beta-lactamase-inducibility mutants of Pseudomonas aeruginosa.
    Livermore DM; Yang YJ
    J Infect Dis; 1987 Apr; 155(4):775-82. PubMed ID: 3102630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbapenemase-producing Pseudomonas aeruginosa in UK.
    Woodford N; Palepou MF; Babini GS; Bates J; Livermore DM
    Lancet; 1998 Aug; 352(9127):546-7. PubMed ID: 9716067
    [No Abstract]   [Full Text] [Related]  

  • 10. Heterogeneity of beta-lactamase production in Pseudomonas maltophilia, a nosocomial pathogen.
    Cullmann W; Dick W
    Chemotherapy; 1990; 36(2):117-26. PubMed ID: 2311440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of N-formimidoyl thienamycin (MK 0787) compared with other beta-lactamase stable cephalosporins against beta-lactamase producing Staphylococcus aureus.
    Ray B; Panja K; Bal M
    Indian J Med Res; 1984 Apr; 79():482-6. PubMed ID: 6333393
    [No Abstract]   [Full Text] [Related]  

  • 12. Factors that influence the evolution of beta-lactam resistance in beta-lactamase-inducible strains of Enterobacter cloacae and Pseudomonas aeruginosa.
    Aronoff SC; Shlaes DM
    J Infect Dis; 1987 May; 155(5):936-41. PubMed ID: 3104483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metallo-β-lactamase-production in meropenem-susceptible Pseudomonas aeruginosa isolates: risk for silent spread.
    Picão RC; Carrara-Marroni FE; Gales AC; Venâncio EJ; Xavier DE; Tognim MC; Pelayo JS
    Mem Inst Oswaldo Cruz; 2012 Sep; 107(6):747-51. PubMed ID: 22990963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of the beta-lactamases of a strain of Pseudomonas aeruginosa, Morganella morganii and Enterobacter cloacae.
    Farmer TH; Reading C
    J Antimicrob Chemother; 1987 Mar; 19(3):401-4. PubMed ID: 3106306
    [No Abstract]   [Full Text] [Related]  

  • 15. A study of the mechanisms involved in imipenem resistance in Pseudomonas aeruginosa isolates from Japan.
    Stunt RA; Thomson CJ; Payne DJ; Amyes SG
    J Antimicrob Chemother; 1998 Aug; 42(2):272-3. PubMed ID: 9738853
    [No Abstract]   [Full Text] [Related]  

  • 16. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.
    Chen HY; Livermore DM
    J Antimicrob Chemother; 1994 May; 33(5):949-58. PubMed ID: 8089068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluation of imipenem/EDTA combined disc and Etest for detection of metallo-beta-lactamase-producing Pseudomonas aeruginosa.
    Bergès L; Rodriguez-Villalobos H; Deplano A; Struelens MJ
    J Antimicrob Chemother; 2007 Apr; 59(4):812-3. PubMed ID: 17317694
    [No Abstract]   [Full Text] [Related]  

  • 18. Beta-lactamase stability and inhibitory activity of meropenem combined with a potent antibacterial activity.
    Nouda H; Harabe ET; Sumita Y; Okuda T; Fukasawa M
    Chemotherapy; 1992; 38(4):218-24. PubMed ID: 1473360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
    Mushtaq S; Vickers A; Woodford N; Livermore DM
    J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. En bloc transduction of imipenem resistance with other resistance determinants from a clinical strain of Pseudomonas aeruginosa.
    Babálová M; Blahová J; Hupková-Lesická M; Krcméry V; Schäfer V
    J Chemother; 1996 Feb; 8(1):43-6. PubMed ID: 8835107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.